Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lin

Showing results (221-230 of 287) with videos related to

Pageof 29
Sort By:
Cancer Research Communications|October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate CancersAilin Zhang, Nathan A Lau, Alicia Wong, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2008
Circulating microRNAs as stable blood-based markers for cancer detectionPatrick S Mitchell, Rachael K Parkin, Evan M Kroh, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
JAMA Oncology|July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A ReviewHeather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.
Pageof 29

Showing results (221-230 of 287) with videos related to

Sort By:
Pageof 29
Cancer Research Communications|October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate CancersAilin Zhang, Nathan A Lau, Alicia Wong, et al.
The Journal of Urology|January 18, 2020
Reply by AuthorsJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
The Journal of Urology|October 26, 2019
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance StudyJeannette M Schenk, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2008
Circulating microRNAs as stable blood-based markers for cancer detectionPatrick S Mitchell, Rachael K Parkin, Evan M Kroh, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
JAMA Oncology|July 25, 2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A ReviewHeather H Cheng, Jeffrey W Shevach, Elena Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.
Pageof 29